Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
Name
Young_Response and resistance.pdf
Size
3.83 MB
Format
Adobe PDF
Checksum (MD5)
259be882686ea6c45b654049992adb20
Author(s)
Shu, Shaokun
Lin, Charles Y.
He, Housheng Hansen
Witwicki, Robert M.
Tabassum, Doris P.
Roberts, Justin M.
Janiszewska, Michalina
Jin Huh, Sung
Liang, Yi
Ryan, Jeremy
Date Issued
January 2016
Journal
Nature
Publisher
Nature Publishing Group
Citation
Shu, Shaokun; Lin, Charles Y.; He, Housheng Hansen; Witwicki, Robert M.; Tabassum, Doris P.; Roberts, Justin M.; Janiszewska, Michalina, et al. “Response and Resistance to BET Bromodomain Inhibitors in Triple-Negative Breast Cancer.” Nature 529, no. 7586 (January 2016): 413–417. © 2016 Macmillan Publishers Limited, part of Springer Nature
Version
Author's final manuscript
Abstract
Triple-negative breast cancer (TNBC) is a heterogeneous and clinically aggressive disease for which there is no targeted therapy. BET bromodomain inhibitors, which have shown efficacy in several models of cancer have not been evaluated in TNBC. These inhibitors displace BET bromodomain proteins such as BRD4 from chromatin by competing with their acetyl-lysine recognition modules, leading to inhibition of oncogenic transcriptional programs. Here we report the preferential sensitivity of TNBCs to BET bromodomain inhibition in vitro and in vivo, establishing a rationale for clinical investigation and further motivation to understand mechanisms of resistance. In paired cell lines selected for acquired resistance to BET inhibition from previously sensitive TNBCs, we failed to identify gatekeeper mutations, new driver events or drug pump activation. BET-resistant TNBC cells remain dependent on wild-type BRD4, which supports transcription and cell proliferation in a bromodomain-independent manner. Proteomic studies of resistant TNBC identify strong association with MED1 and hyper-phosphorylation of BRD4 attributable to decreased activity of PP2A, identified here as a principal BRD4 serine phosphatase. Together, these studies provide a rationale for BET inhibition in TNBC and present mechanism-based combination strategies to anticipate clinical drug resistance.
MIT Department
Broad Institute of MIT and Harvard
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1038/nature16508
